Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Asymmetric High-Flow Nasal Cannula During Pulmonary Rehabilitation in COPD

NCT: NCT07497230 · COMPLETED

NCT IDNCT07497230
StatusCOMPLETED
Start Date2025-05-02
Completion2025-09-20

Brief Summary

This randomized pilot trial evaluated the feasibility and preliminary effects of using asymmetric high-flow nasal cannula (A-HFNC) during exercise-based pulmonary rehabilitation (PR) in patients with chronic obstructive pulmonary disease (COPD). Thirty patients were randomly assigned to conventional PR or PR supplemented with A-HFNC during aerobic training, completing 12 supervised sessions. The study assessed whether A-HFNC could be safely and acceptably incorporated into PR, and whether it enabled higher training intensity and improved exercise performance. Results showed that the intervention was feasible and safe, with 83% adherence in both groups and no adverse events. Patients in the A-HFNC group trained at significantly higher treadmill inclination and showed a clinically meaningful trend toward greater improvement in maximal exercise tolerance. These findings support the design of a larger definitive trial.

Frequently Asked Questions

What is Asymmetric High-Flow Nasal Cannula During Pulmonary Rehabilitation in COPD?

Asymmetric High-Flow Nasal Cannula During Pulmonary Rehabilitation in COPD is a clinical trial registered under NCT07497230. Current status: COMPLETED.

What is the status of NCT07497230?

The current status of NCT07497230 (Asymmetric High-Flow Nasal Cannula During Pulmonary Rehabilitation in COPD) is: COMPLETED.

When did Asymmetric High-Flow Nasal Cannula During Pulmonary Rehabilitation in COPD start?

Asymmetric High-Flow Nasal Cannula During Pulmonary Rehabilitation in COPD started on 2025-05-02.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.